Amin Benyounes, MD
Medical Oncology · Fairfax, VANPI 1326487935
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $293 of the $360 with a category attached, or 81.4%. 5 manufacturers reported payments, led by Pharmacyclics LLC, An Abbvie Company at 43.3% of the total. Reporting peaked in 2022 at $140 and has fallen 52.1% since, to $67 in 2025. That places this record below the midpoint for medical oncology clinicians in VA, where the typical reported total is $926.
Across 9 payments — averaging $40.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pharmacyclics LLC, An Abbvie Company$156
- Jazz Pharmaceuticals Inc.$107
- GSK$67
- Boston Scientific$19
- E.r. Squibb & Sons, L.L.C.$12
Across 12 payments — averaging $68,620 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$677K
- Genentech, Inc.$80K
- Merck$33K
- Daiichi Sankyo Inc.$33K
What the payments were for
- Food & beverage$29381%
- Education$6719%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | 5 | $156 |
| Jazz Pharmaceuticals Inc. | 1 | $107 |
| GSK | 1 | $67 |
| Boston Scientific | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZEPZELCA$107
How this compares
$360 in reported general payments places this provider in the 35th percentile of 95 medical oncology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 85 | $1,495,018 |
| AlecensaAlectinib Hcl | 21 | $383,772 |
| LorbrenaLorlatinib | 12 | $251,053 |
| EliquisApixaban | 54 | $30,567 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $7,240 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 20 | $2,109 |
| Oxycodone Hcl | 62 | $1,162 |
| Dexamethasone | 46 | $786 |
| Morphine Sulfate ErMorphine Sulfate | 22 | $613 |
| Ventolin HfaAlbuterol Sulfate | 11 | $593 |
| Ondansetron Hcl | 51 | $544 |
| Prochlorperazine Maleate | 40 | $447 |
| Gabapentin | 39 | $256 |
| Lidocaine Hcl ViscousLidocaine Hcl | 12 | $237 |
| Megestrol Acetate | 11 | $165 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $67 | $7,24012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 95 medical oncology providers in Virginia.
Other medical oncology in Fairfax
- Janakiraman SubramanianFairfax$562K
- Alexander SpiraFairfax$533K
- Roy BeveridgeFairfax$216K
- Kathleen HarndenFairfax$195K
- Nagla Abdel KarimFairfax$131K
- Lauren MauroFairfax$53K
- Donald TrumpFairfax$20K
- Timothy CannonFairfax$11K
- Arthur WinerFairfax$10K
- Danijela JelovacFairfax$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.